Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13698249 | 0.72 | KMT2A (0.49) | KMT2ATSHRCYP19A1TP53ACHE | |
| SCHEMBL30477683 | 0.68 | TP53 (0.44) | TSHRTP53MAPTALDH1A1HTT | |
| SCHEMBL16212244 | 0.68 | TP53 (0.44) | TSHRTP53MAPTALDH1A1HTT | |
| SCHEMBL10415997 | 0.67 | GABRP (0.43) | KMT2AACHEMEN1MAPTHTT | |
| SCHEMBL7436894 | 0.67 | DPP4 (0.46) | KMT2ATSHRTP53MEN1MAPT | |
| SCHEMBL13698259 | 0.67 | CYP19A1 (0.59) | KMT2ATSHRCYP19A1 | |
| SCHEMBL3886406 | 0.66 | GPBAR1 (0.49) | KMT2ATSHRTP53ALDH1A1CYP1A2 | |
| SCHEMBL6951189 | 0.66 | IDO1 (0.61) | KMT2AMEN1MAPTHTT | |
| Phensuximide SCHEMBL35333 | 0.66 | KMT2A (1.00) | KMT2ATSHRCYP19A1MEN1MAPT | |
| Phensuximide SCHEMBL35334 | 0.66 | KMT2A (1.00) | KMT2ATSHRCYP19A1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | KMT2A 998/4885TSHR 1995/4885CYP19A1 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.